SGLT-2 Inhibitor–ARB Composition for Cardiovascular Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional drug treatments for cardiovascular diseases, particularly in patients with hypertension and diabetes, often fail to effectively control blood pressure and are associated with low medication compliance and harmful side effects, necessitating the development of combination therapies with fewer adverse effects.
Innovation Solution
A pharmaceutical composition combining an angiotensin II receptor blocker and a sodium-glucose cotransporter-2 inhibitor, such as Telmisartan and Dapagliflozin, is developed to synergistically treat cardiovascular diseases like hypertension and heart failure, with optimal dosages and formulations to minimize drug-drug interactions and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drug treatment methods are used for patients with hypertension with diabetes, then blood pressure control is attempted, but therapeutic effect is poor and medication compliance is low
Solution Approach 1:
The patent combines two drugs with different mechanisms of action (SGLT-2 inhibitor and ARB) into a single pharmaceutical composition. This merging approach allows simultaneous blood pressure control and blood sugar management, improving therapeutic effect while reducing the number of pills patients need to take, thereby enhancing medication compliance
2Reliability
If patients take multiple drugs in large doses to treat hypertension with diabetes, then more comprehensive coverage is achieved, but harmful side effects increase and medication compliance decreases
Solution Approach 1:
The patent optimizes the dosage parameters of the combined drugs, using lower individual doses of SGLT-2 inhibitor and ARB compared to conventional monotherapy. This parameter change reduces harmful side effects while maintaining comprehensive therapeutic coverage through the synergistic combination of the two drugs
3Adaptability or versatility
If combination therapies with drugs of different mechanisms are used, then broader therapeutic coverage is achieved, but drug-drug interactions and harmful side effects may occur
Solution Approach 1:
The patent uses a specific formulation approach where the two drugs (SGLT-2 inhibitor and ARB) act as intermediaries that work through different physiological pathways without interfering with each other's mechanisms. The SGLT-2 inhibitor acts on renal glucose reabsorption while the ARB acts on angiotensin II receptor blockade, providing broad therapeutic coverage without significant drug-drug interactions
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3~4
AI summary
The present disclosure relates to a pharmaceutical composition for the prevention or treatment of cardiovascular disease, comprising a sodium glucose cotransporter-2 inhibitor and an angiotensin II receptor blocker, which is free from drug-drug interaction issues, has a synergistic effect on the prevention or treatment of cardiovascular disease, and can be effectively applied to patients with cardiovascular diseases, in particular heart failure.